

# NCI Director's Report

---

Norman E. Sharpless, M.D.


*4<sup>th</sup> Virtual Meeting of the Board of Scientific  
Advisors and National Cancer Advisory Board  
June 14, 2021*

@NCIDirector  
@TheNCI

# NCI Appropriations

## FY 2015 – 2022 (in millions)

21<sup>st</sup> Century Cures Act - orange  
Childhood Cancer Initiative - green



# NCI COVID-19 in Cancer Patients Study (NCCAPS)

**875**

TRIAL SITES  
ACTIVATED  
IN

**50**

STATES  
+ DC, PUERTO  
RICO, AND  
CANADA

Special emphasis on  
minority,  
underserved and  
rural communities

Participants  
will be  
followed for  
2 years

**1,137**  
ENROLLED

88 pediatric patients  
enrolled

Launched May 21, 2020  
Conception to Launch in  
6 weeks


Aims to enroll  
2,000 patients  
across 1,000  
sites in U.S.

ASCO 21  
ABSTRACTS

**#6565**  
**#6566**


# COVID-19 SeroHub: US seroprevalence trends

## April 2020 – February 2021




# Impact of COVID-19 pandemic on cancer screening in the US

**Breast Cancer Screening  
(Mammography)**



**Colorectal Cancer Screening  
(Colonoscopy and FIT)**



*Cancer Screening During the Coronavirus Disease-2019 Pandemic: A Perspective From the National Cancer Institute's PROSPR Consortium. Gastroenterology, Volume 160, Issue 4, 999 - 1002*

# NCI Equity and Inclusion Program

<b>EQUITY COUNCIL</b>	<b>Chair</b> Ned Sharpless  <b>Co-Chair</b> Paulette Gray	Mark Alexander Andrea Apolo Nelvis Castro Bob Croyle	Montse Garcia-Closas Anne Lubenow Ji Luo	Donna Siegle Dinah Singer Sanya Springfield
<b>WORKING GROUP 1</b> <i>Enhancing Research to Address Cancer Health Disparities</i>  <b>CO-CHAIRS</b>  Jim Doroshow Worta McCaskill-Stevens Tiffany Wallace	<b>WORKING GROUP 2</b> <i>Ensuring Diversity of Thought and Background in the Cancer Research Workforce</i>  <b>CO-CHAIRS</b>  LeeAnn Bailey Susan McCarthy Glenn Merlino	<b>WORKING GROUP 3</b> <i>Promoting an Inclusive and Equitable Community at NCI</i>  <b>CO-CHAIRS</b>  Shannon Bell Satish Gopal Paige Green	<b>WORKING GROUP 4</b> <i>Systematic Tracking and Evaluation of Equity Activities</i>  <b>CO-CHAIRS</b>  Michelle Bennett Doug Lowy	<b>WORKING GROUP 5</b> <i>Communications and Outreach for Equity Activities</i>  <b>CO-CHAIRS</b>  Peter Garrett Angela Jones Anita Linde

# 2021




# Core Registries





# Research Support

## Registries



# Cancer Moonshot<sup>SM</sup>





## Human Tumor Atlas Network Data Portal

Welcome to the HTAN Data Portal!

The Human Tumor Atlas Network (HTAN) is a National Cancer Institute (NCI)-funded Cancer Moonshot<sup>SM</sup> initiative to construct 3-dimensional atlases of the dynamic cellular, morphological, and molecular features of human cancers as they evolve from precancerous lesions to advanced disease.

Explore the Data

9

Atlases

8

Organs


509

Cases

1260

Biospecimens

# Over 50,000 oncology patients reached by an NCI Cancer Center Cessation Initiative (C3I) tobacco treatment program since 2018



*Courtesy of Dr. Betsy Rolland, C3I PI. Data through April 15, 2021.*




## Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N.J. Tutt, M.B., Ch.B., Ph.D., Judy E. Garber, M.D., M.P.H., Bella Kaufman, M.D., Giuseppe Viale, M.D., Debora Fumagalli, M.D., Ph.D., Priya Rastogi, M.D., Richard D. Gelber, Ph.D., Evandro de Azambuja, M.D., Ph.D., Anitra Fielding, M.B., Ch.B., Judith Balmaña, M.D., Ph.D., Susan M. Domchek, M.D., Karen A. Gelmon, M.D., et al., for the OlympiA Clinical Trial Steering Committee and Investigators\*

3-year invasive disease-free survival	Placebo <b>77.1%</b>	3-year distant disease-free survival	Placebo <b>80.4%</b>
	Olaparib <b>85.9%</b>		Olaparib <b>87.5%</b>
<i>Difference: 8.8 percentage points 95% CI: 4.5 to 13.0.</i>		<i>Difference: 7.1 percentage points 95% CI: 3.0 to 11.1</i>	

# Proteogenomic and metabolomic characterization of human glioblastoma

- Phosphorylated PTPN11 and PLCG1 represent a signaling hub in RTK-altered tumors
- Four immune GBM subtypes exist, characterized by distinct immune cell populations
- Mesenchymal subtype EMT signature is specific to tumor cells, but not to stroma
- Histone H2B acetylation is enriched in classical GBMs with low macrophage content





# U.S.-U.K. Bilateral Cancer Summit



Doug Mills/The New York Times

*“We will convene the first U.S.-U.K. Bilateral Cancer Summit and bring together researchers, patients, and other stakeholders to share ideas and identify opportunities for collaboration to accelerate advances in lifesaving approaches to cancer, which remains a leading cause of death worldwide.”*

- Joint statement issued June 10, 2021

# National Cancer Act of 1971 50<sup>th</sup> Anniversary



# Discussion